SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Deviation from the plan, path or norms. Choosing an alternative way, changing the plans and flexibility.
Obesity
Terns Turns Away From Obesity Pill After ‘Uncompetitive’ Phase II Profile
Two patients experienced grade 3 liver enzyme elevations that were deemed related to Terns’ investigational obesity pill TERN-601.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Cambridge, Massachusetts, USA - 30 July 2024. Takeda Pharmaceutical Company logo on office building.Biotech industry
Antibody-drug conjugate (ADC)
Takeda Bets up to $11.4B for Up To Three Innovent Cancer Assets
For $1.2 billion upfront and up to $10.2 billion in milestones, Takeda will gain access to a bispecific antibody fusion protein targeting both the PD-1 and IL-2 pathways, among other assets.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Human head with puzzle pieces and doodles vector illustration. Human brain lacking a piece of puzzle. Concept of brain function, memory loss, disorder, dementia. Abstract human head profile
Neuropsychiatric disorders
Alector Scraps Dementia Drug After Phase III Flop, Lays Off 49% of Staff
This represents Alector’s second failed neurodegenerative asset in a year, after an AbbVie-partnered asset missed in Alzheimer’s last November. On latozinemab for frontotemporal dementia, Alector was working with GSK, which fronted $700 million in 2021 to collaborate on two programs.
October 22, 2025
 · 
2 min read
 · 
Tristan Manalac
Gold bull and bear on each side of a wooden seesaw in gradient blue background. Illustration of the concept of bullish and bearish market, change of stock prices and risk of investment
Venture capital
Biotech Markets Turn Positive but Experts Say Don’t Call It a Comeback—Yet
M&A is back, the S&P XBI is rising again, a biotech pulled off an IPO and positive data is pulling in investors again. This may just be the industry’s new normal.
October 22, 2025
 · 
7 min read
 · 
Annalee Armstrong
Podcast
Novo Board Upended, ESMO Excitement, FDA Awards, Replimune’s U-Turn
Novo Nordisk’s leadership gets another shake-up as President Trump promises to significantly slash prices for its GLP-1 drugs; Summit/Akeso, Exelixis and more present new data at ESMO 2025; Replimune pops as FDA accepts resubmitted BLA; FDA names first winners of Commissioner’s National Priority Voucher program; and more.
October 22, 2025
 · 
1 min read
 · 
Heather McKenzie
Employees walk toward exit
Leadership
Leadership Lab: How To Spot When Employees Are About To Walk Away
Employees rarely leave companies for one reason alone. In this column, Kaye/Bassman’s Michael Pietrack shares a framework that helps leaders identify when their team members are thinking about heading for the exit—and how to address it.
October 22, 2025
 · 
7 min read
 · 
Michael Pietrack
Hand touches AI artificial intelligence, digital data and future technology. Futurism, robot computer software, digital twin, blockchain, virtual technology.
Opinion
C-Suite Leaders Must Harness AI as a Partner and a Tool
AI is changing the nature of leadership in biopharma. Here’s how executives can not only adapt, but lead the way.
October 22, 2025
 · 
3 min read
 · 
Petra Jantzer
Man figure stopping the domino effect. Executive and risk control concept. 3D rendering
Patents
How J&J Kept Growing Amid the Erosion of Cornerstone Drug Stelara
The company cut back in areas while investing in internal and external opportunities to offset the loss of exclusivity on a product that until recently accounted for 20% of innovative medicine sales.
October 22, 2025
 · 
5 min read
 · 
Nick Paul Taylor
Unhappy young woman feel lonely abandoned in crowd suffer from communication lack. Upset girl struggle with depression or mental disorder. Psychological problem. Flat vector illustration.
Neuropsychiatric disorders
Neuphoria’s Social Anxiety Drug Flunks Late-Stage Trial
The company is dropping its social anxiety disorder program but will still test the molecule in post-traumatic stress disorder.
October 21, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS